PuDeRegels

Pulmonary delivery of anticancer drug via an inhaled responsive nanogel with stealth ability and high targetability

Project status
In progress
Source of funding
EUROPEAN FUNDS - HORIZON EUROPE - WIDERA-2022-TALENTS-02
Implementation period
FEB 15, 2024 - FEB 14, 2026
NHRF budget
€169326
Total budget
€169326
Project ID number
101090325

This project aims to investigate and develop nanogels incorporated into microgels containing encapsulated anticancer drugs. These nanogels are intended to be delivered via the respiratory system to the lungs, where they will selectively swell and release the therapeutic agents. Particular emphasis is placed on targeting moieties, stealth functionalities, and biocompatibility.

Drug delivery for lung cancer remains limited but is increasingly under investigation. Key challenges for this type of technology include the efficient encapsulation of the bioactive compound within a nanocarrier, targeted delivery, controlled drug release, compatibility with lung tissue, and avoidance of clearance by macrophages.

The development of new methodologies for improved therapeutic delivery is of significant importance at both national and international levels. New materials and technologies continue to emerge annually. Currently, lung cancer treatment relies primarily on intravenous therapies. However, pulmonary drug delivery represents a promising alternative approach for directly targeting the affected area in the lung. Although not a novel technology, pulmonary delivery is currently restricted to specific diseases and conditions.

The research builds on the existing expertise of the experienced researcher (ER) in polymer science and leverages the host institute’s strengths in chemical biology, drug research, and biotechnology. The project is expected to result in several high-impact publications and facilitate knowledge and technology transfer that can be exploited at an industrial level. This will contribute to the scientific output, international visibility, and economic development of Europe.

The fellowship is anticipated to support the reintegration of the ER into a long-term academic position following an extensive research career in the academic sector in Spain. Upon completion of the project, the ER is expected to gain new knowledge and training, establishing a solid foundation for future opportunities in both academia and industry.

Project status
In progress
Source of funding
EUROPEAN FUNDS - HORIZON EUROPE - WIDERA-2022-TALENTS-02
Implementation period
FEB 15, 2024 - FEB 14, 2026
NHRF budget
€169326
Total budget
€169326
Project ID number
101090325
Principal Investigator
Senior Researcher